Amar Kishan, Radiation Oncologist, Professor, and Executive Vice Chair of Radiation Oncology at UCLA, shared Sean Collins’s post on X, adding:
“SBRT for high-risk PCa: 2026 update from the SHARP consortium out in European Urology Oncology.
Excellent BCRFS and DMFS outcomes. Non-randomized, but dose escalation to 40 Gy with at least 12 mos of ADT performs extremely well.”
Sean Collins, Radiation Oncologist at University of South Florida, shared a post on X, about a recent article he and his colleagues co-authored, adding:
“Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients – European Urology Oncology.”
Title: Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients
Authors: Luca Valle, Tahmineh Romero-Kalbasi, Tommy Jiang, Ritchell van Dams, Donald Fuller, Andrew Loblaw, Thomas Kennedy, Sean Collins, Vaibhav Sharma, Simeng Suy, Vedang Murthy, Indranil Mallick, Nicholas Nickols, Neil Desai, Raquibul Hannan, Nima Aghdam, Irving Kaplan, Kevin Stephans, Rahul Tendulkar, Steven Lau, Kekoa Taparra, Michael Steinberg, Amar Kishan
Read the Full Article on European Urology Oncology
More posts featuring Amar Kishan.